Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2002
11/14/2002CA2446528A1 Disinfecting and solubilizing steroid compositions
11/14/2002CA2446204A1 Anti-virus agent
11/14/2002CA2446060A1 Compositions and delivery systems for administration of a local anesthetic agent
11/14/2002CA2445985A1 Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
11/14/2002CA2445933A1 Gelatin substitute
11/14/2002CA2445065A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002CA2444718A1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
11/13/2002EP1256354A1 Methods for treating cancer
11/13/2002EP1256346A1 Remedies for external use for allergic skin diseases
11/13/2002EP1256340A1 Improved transdermal therapeutic system for the treatment of Parkinson's disease
11/13/2002EP1256339A1 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
11/13/2002EP1256336A2 Two-phase gel composition
11/13/2002EP1255845A2 Modified cytokines for use in cancer therapy
11/13/2002EP1255823A1 Slow release protein polymers
11/13/2002EP1255793A1 Powder material for electrostatic application to a substrate and electrostatic application of the powder material to a substrate
11/13/2002EP1255780A1 Methods and compositions for generating human monoclonal antibodies
11/13/2002EP1255725A2 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
11/13/2002EP1255576A1 Mineral-polymer hybrid composition
11/13/2002EP1255570A2 Matrix metalloproteinase inhibitors as targeting components in diagnostic agents
11/13/2002EP1255568A2 Conjugates targeted to target receptors
11/13/2002EP1255567A1 Selective cellular targeting: multifunctional delivery vehicles
11/13/2002EP1255566A2 Preparation of aqueous clear solution dosage forms with bile acids
11/13/2002EP1255565A1 Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
11/13/2002EP1255563A1 Composition of antigen and glycolipid adjuvant sublingual administration
11/13/2002EP1255558A1 Uses of agonists and antagonists to modulate activity of tnf-related molecules
11/13/2002EP1255557A1 Stable, nasally, orally or sublingually applicable pharmaceutical preparation
11/13/2002EP1255552A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
11/13/2002EP1255545A2 L-arginine in combination with other compounds for treating cardiovascular diseases
11/13/2002EP1255544A1 Mucin synthesis inhibitors
11/13/2002EP1255535A2 Controlled release pharmaceutical composition containing tramadol hydrochloride
11/13/2002EP1255534A2 Method for the preparation of microspheres which contain colloidal systems
11/13/2002EP1255532A1 Osmotically-driven fluid dispenser and coating composition
11/13/2002EP1255445A1 Method of filtration of a dairy stream
11/13/2002EP1255439A1 Therapeutic platelets and methods
11/13/2002EP1140200B1 Anthraquinone anticancer drugs
11/13/2002EP1084146B1 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
11/13/2002EP0991407B9 Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
11/13/2002EP0777477B1 Improved pharmaceutical formulations containing ibuprofen and codeine
11/13/2002EP0756496B1 Dendrimeric compounds
11/13/2002EP0735863B1 Accelerated release composition containing bromocriptine
11/13/2002EP0697889B1 COMBINED TREATMENT OF IRON DEPLETION AND IgG ANTIBODY
11/13/2002EP0693935B1 Method and compositions for digesting tissue
11/13/2002EP0618807B1 A stabilized pharmaceutical formulation comprising growth hormone and histidine
11/13/2002CN1379821A Nucleic acid transporter containing polypeptide and recombinant virus vector
11/13/2002CN1379769A Novel composition and method or stabilizing same
11/13/2002CN1379768A Improved aqueous solubility pharmaceutical formulations
11/13/2002CN1379687A Magnetic nanoparticles having biochemial activity, method for production thereof and their use
11/13/2002CN1379684A Treating prostate cancer with anti-ErbB2 antibodies
11/13/2002CN1379683A 疫苗 Vaccine
11/13/2002CN1379678A Method for calming human beings using personal care compositions
11/13/2002CN1379674A Ciclesonide contained pharmaceutical composition for application to mucosa
11/13/2002CN1379673A Ciclesonide-containing aqueous pharmaceutical composition
11/13/2002CN1379669A Valdecoxib compositions
11/13/2002CN1379667A Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use
11/13/2002CN1379663A Vaccine composition and method of using same
11/13/2002CN1379623A Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
11/13/2002CN1379068A Low foaming N-alkyl-tartraimine and N-alkyl melicimine wetting agent
11/13/2002CN1379052A Polyasparamide derivative and process for preparing its nano capsules
11/13/2002CN1379047A Match of organic medicine and beta-cyclodextrin derivative and its preparing process
11/13/2002CN1094063C Methods for preparing monomeric calicheamicin derivative/carrier conjugates
11/12/2002US6479637 Hemoglobin-haptoglobin complexes
11/12/2002US6479627 Aqueous preparation of lactoferrin having improved stability
11/12/2002US6479551 Treatment of migraine headache
11/12/2002US6479541 Amiodarone-containing parenteral administration
11/12/2002US6479540 Compositions of tocol-soluble therapeutics
11/12/2002US6479529 Antioxidant stabilizer system for pharmaceutical formulations
11/12/2002US6479496 Treating a human patient suffering from variant and exercise-induced angina by administering a sustained release pharmaceutical dosage form including at least 50% by weight ranolazine in no more than two tablets per dose
11/12/2002US6479468 Oxidized and reduced polysaccharide exhibits a longer vascular half-life than unmodified starch, slower degradation by amylase than unmodified starch, and/or slower the smaller the allergenicity
11/12/2002US6479461 Use of alkylmonoglucosides as molecular vectors
11/12/2002US6479457 Polypeptide comprising at least one effective ionogenic amine ionically bound to polymer; drug delivery systems for the controlled release of pharmaceutical polypeptides
11/12/2002US6479076 Nicotine delivery compositions
11/12/2002US6479074 Methods and transdermal compositions for pain relief
11/12/2002US6479067 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
11/12/2002US6479060 Elegant hydrogenated castor oil ointments
11/12/2002US6479058 Composition for the topical treatment of poison ivy and other forms of contact dermatitis
11/12/2002US6479049 Methods and compositions for the dry powder formulation of interferons
11/12/2002US6479048 Foam inhibitor comprising hydrophobic amino acid which is suitable for inhibiting foaming induced when dissolving a dry composition containing saccharide; preferably has a hydropathy index of not less than 2.
11/12/2002US6479045 Vaginal pH buffering for preventing miscarriage and premature labor, by treating or preventing bacterial vaginosis
11/12/2002US6479039 Antimicrobial artificial nail composition and methods for preparing and using same
11/12/2002US6479035 Pharmaceutical formulation of fluticasone propionate
11/12/2002US6479034 Method of preparing gas and gaseous precursor-filled microspheres
11/12/2002US6479033 Antitumor cystostatic and contrast agent
11/12/2002CA2266478C Polymerizable biodegradable polymers including carbonate or dioxanone linkages
11/12/2002CA2204535C Molecules that home to a selected organ or tissue in vivo and methods of identifying same
11/12/2002CA2195318C Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
11/12/2002CA2119109C Bioadhesive ophthalmic insert
11/12/2002CA2101227C Chlorophyll and bacteriochlorophyll derivatives and pharmaceutical compositions containing them
11/12/2002CA2090920C Opacifier for water-based compositions
11/12/2002CA2088917C Therapeutic ribozyme compositions
11/12/2002CA2088289C Pharmaceutically active composition extracted from tanacetum parthenium, process for its extraction, and pharmaceutical composition containing same
11/12/2002CA2071518C Oral composition for the treatment of inflammatory bowel diseases
11/12/2002CA2049668C Bioerodible implants
11/12/2002CA2038637C Pharmaceutical iodine compositions
11/12/2002CA2009533C Novel cyclosporin galenic forms
11/11/2002CA2385510A1 Use of hydroxyflavanones for masking bitter taste
11/07/2002WO2002088664A2 Control of compactability through crystallization
11/07/2002WO2002088374A1 Process for producing isomaltose and use thereof
11/07/2002WO2002088318A2 Lipid-comprising drug delivery complexes and methods for their production
11/07/2002WO2002088246A1 Molded object having high pullulan content, process for producing the same, and use thereof
11/07/2002WO2002087624A2 Uses of chemically-modified cholinesterases for detoxification of organophosphorus compounds